BioMarin Pharma Buying LEAD Therapeutics
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has agreed to acquire LEAD Therapeutics Inc., a San Bruno, Calif.-based drug company whose lead product is for patients with rare, genetically-defined cancers. The deal could be worth upwards of $97 million, including an $18 million up-front payment. LEAD has raised around $22 million in VC funding from ProQuest Investments, Pappas Ventures and Mustang Ventures.
5 February 2010•4 mins read
